Saturday 17 October 2026 Export RXST’s income statement to Excel — free account

RxSight, Inc.

RxSight, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $134.5 million, down 3.89% from fiscal 2024. In the quarter to June 2026, revenue was flat, EPS was flat and free cash flow fell 94.4%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.

4.51 0.16 −3.43%

Follow RXST

Alert me

Market cap: $194.2M
P/E: 0.0×
Fwd P/E: −3.5×
Dividend yield: —
F-score: 3/9
Altman Z: 5.03
Beneish M: −3.15
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 0.12

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	4	—

Insider Ownership 7.02%

Capital & Financial Ratios $m

Market Cap 194.24

Revenue 127.58

Net Income (46.95)

Free Cash Flow (27.16)

Net Debt (208.80)

Current Ratio 4.07

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E (3.53)

P/S ratio 1.47

P/B ratio 0.71

Past 5Y EPS Growth —

This Y EPS Growth 0.66%

Next Y EPS Growth (23.42%)

Next Y revenue growth 9.39%

Next 5Y EPS Growth 10.81%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 0.08%

10-year low 10-year high

P/B against its own 10 years 0.16%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2025	Powerpack
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	127	237	228	209
Receivables	20	30	23	79
Inventory	17	22	32	37
Other	—	—	—	—
	168	294	287	327

	2023	2024	2025	Q'26
Payables	4	5	5	6
ST’ Debt	—	—	—	—
Other	—	—	—	50
	21	26	26	80

Compound Annual Growth %

	10y	5y	3y
Sales	—	55.74%	40.00%
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	152.50%	45.28%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	31	34	—	—	—
’25	38	34	30	33	134
’24	30	35	35	40	140
’23	17	21	22	29	89
’22	9	11	13	16	49
’21	3	5	6	8	23
’20	—	3	4	—	15

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(11)	(10)	—	—	—
’25	(9)	(4)	(1)	(1)	(16)
’24	(9)	(4)	1	(4)	(17)
’23	(18)	(8)	(8)	(8)	(42)
’22	(15)	(15)	(15)	(14)	(59)
’21	(10)	(12)	(14)	(9)	(45)
’20	—	(20)	(7)	(8)	(35)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(12)	(11)	—	—	—
’25	(9)	(6)	(2)	(2)	(19)
’24	(11)	(6)	0	(5)	(22)
’23	(19)	(9)	(9)	(10)	(46)
’22	(15)	(16)	(16)	(14)	(61)
’21	(11)	(13)	(14)	(9)	(47)
’20	—	(21)	(8)	(9)	(38)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.38)	(0.29)	—	—	—
’25	(0.20)	(0.29)	(0.24)	(0.22)	(0.95)
’24	(0.25)	(0.16)	(0.16)	(0.15)	(0.71)
’23	(0.42)	(0.40)	(0.35)	(0.26)	(1.41)
’22	(0.64)	(0.61)	(0.61)	(0.56)	(2.41)
’21	(1.70)	(3.53)	(0.68)	(0.58)	(3.57)
’20	—	—	—	—	4.98

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	—	—	—	9.18	8.80	12.06	33.03	6.32	Analyst estimates 2026–2028 Powerpack
	High	—	—	—	—	—	19.67	16.99	41.43	66.54	37.13
People
People	Employees	—	—	—	—	171	221	292	374	498	461
	Revenue/emp, $m	—	—	—	0.00	0.09	0.10	0.17	0.24	0.28	0.29
Income, $m
Income, $m	Revenue	—	—	—	2	15	23	49	89	140	134
	Gross margin, %	—	—	—	(81.17)	11.62	19.99	43.52	60.36	70.71	76.60
	EBT	—	—	—	126	28	(49)	(67)	(49)	(27)	(39)
	EBT margin, %	—	—	—	5,633.38	188.25	(215.46)	(136.20)	(54.55)	(19.59)	(28.91)
	Net income	—	0	—	108	28	(49)	(67)	(49)	(27)	(39)
	Depreciation	—	—	—	4	4	4	3	(2)	(5)	(5)
Per share, $
Per share, $	Revenue	—	—	—	0.08	3.96	1.66	1.77	2.59	3.60	3.29
	Earnings	—	—	—	0.95	7.44	(3.57)	(2.41)	(1.41)	(0.71)	(0.95)
	Cash flow	—	—	—	(1.47)	(9.50)	(3.28)	(2.13)	(1.21)	(0.44)	(0.38)
	Capex	—	—	—	0.00	(0.68)	(0.14)	(0.09)	(0.14)	(0.14)	(0.09)
	Free cash flow	—	—	—	(1.47)	(10.18)	(3.42)	(2.21)	(1.35)	(0.58)	(0.47)
	Book value	—	—	—	0.83	0.72	10.15	3.25	4.65	7.24	6.75
	Shares, m	—	—	—	28	4	14	28	34	39	41
Valuation, ×
Valuation, ×	P/E	—	—	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	—	—	—	4.31	4.31	6.78	7.21	14.18	9.55	3.17
	P/B	—	—	—	0.00	0.00	1.11	3.93	7.87	4.75	1.54
	EV/Sales	—	—	—	2.85	2.85	1.49	5.87	12.97	7.99	1.61
	EV/FCF	—	—	—	(1.09)	(1.09)	(0.72)	(4.70)	(24.89)	(49.97)	(11.23)
Cash, $m
Cash, $m	Operating cash flow	—	—	—	(41)	(35)	(45)	(59)	(42)	(17)	(16)
	Capex	—	—	—	(4)	(3)	(2)	(2)	(5)	(5)	(4)
	Free cash flow	—	—	—	(41)	(38)	(47)	(61)	(46)	(22)	(19)
Balance, $m
Balance, $m	Working capital	—	—	—	82	70	165	117	148	268	261
	Total debt	—	—	—	6	24	40	40	—	—	—
	Net debt	—	—	—	(75)	(45)	(120)	(66)	(127)	(237)	(228)
	Shareholders’ equity	—	—	—	23	3	138	90	160	281	276
Returns, %
Returns, %	ROA	—	—	—	47.32	3.19	(33.19)	(38.94)	(29.22)	(10.96)	(12.36)
	ROIC	—	—	—	0.00	0.00	(176.71)	(163.06)	(94.34)	(52.34)	(63.34)
	ROE	—	—	—	0.00	(1.03)	45.85	(58.52)	(38.85)	(12.43)	(13.99)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
CATX Perspective Therapeutics, Inc.	$267.1M	— (loss-making)	— (loss-making)	−72.07% (below 0%: shrinking)	n/m	−66.09% (below 0%: shrinking)	100.00%	(36,120.99%)	Compare
LAB Standard BioTools Inc.	$258.5M	2.9×	— (loss-making)	−7.62% (below 0%: shrinking)	n/m	+52.76% (above 0%: growing)	52.40%	(126.28%)	Compare
TLSI TriSalus Life Sciences, Inc.	$240.1M	— (loss-making)	— (loss-making)	+1.73% (above 0%: growing)	n/m	−41.29% (below 0%: shrinking)	86.78%	(86.03%)	Compare
ELMD Electromed, Inc.	$232.3M	20.0×	25.5×	+11.64% (above 0%: growing)	+57.69% (above 0%: growing)	−25.15% (below 0%: shrinking)	78.71%	19.70%	Compare
PROF Profound Medical	$230.5M	— (loss-making)	— (loss-making)	+12.30% (above 0%: growing)	n/m	+17.51% (above 0%: growing)	78.41%	(445.67%)	Compare
RXST RxSight, Inc.	$194.2M	— (loss-making)	— (loss-making)	+0.31% (above 0%: growing)	n/m	−94.39% (below 0%: shrinking)	76.72%	(40.81%)
INGN Inogen, Inc	$167.1M	— (loss-making)	— (loss-making)	+3.04% (above 0%: growing)	n/m	−51.15% (below 0%: shrinking)	45.51%	(5.36%)	Compare
STIM Neuronetics, Inc.	$148.6M	— (loss-making)	— (loss-making)	+9.08% (above 0%: growing)	n/m	+62.06% (above 0%: growing)	51.06%	(3.61%)	Compare
QTRX Quanterix Corporation	$145.2M	— (loss-making)	— (loss-making)	+34.44% (above 0%: growing)	n/m	+18.92% (above 0%: growing)	38.52%	(150.22%)	Compare
Median of peers	$231.4M	—	—	+6.06%	—	−3.82%	65.41%	(106.15%)

All 149 Medical Devices stocks →

RxSight, Inc. (RXST) key facts

Concern: RxSight, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $134.5 million, down 3.89% from fiscal 2024.
RxSight, Inc. (RXST) is a Medical Devices company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, RXST traded at $4.51, a market capitalization of $194.2 million.
Return on equity was −14.0% and debt-to-equity 0.00.
Its Piotroski F-score is 3 out of 9 and its Altman Z-score is 5.03 (safe zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.